NOA-20 / N²M²
Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Master Match – N²M² (NOA-20)
The increasing individualization of cancer therapy is reflected by novel study concepts such as umbrella or basket studies. While in basket studies patients with different tumor indications but the same genetic alteration are treated in a common protocol, in umbrella studies patients of one tumor indication are tested for different alterations, for which different targeted therapies are then offered.
The goal of these early Phase I/II studies is to obtain initial insights regarding safety and efficacy and to achieve rapid prioritization of new active substances for clinical application. NCT Neuro Master Match (N²M²) will treat patients with newly diagnosed glioblastoma without hypermethylation of the methylguanine DNA methyltransferase promoter after extensive molecular testing by assignment with a molecularly targeted therapy or by randomization for a control treatment or immunomodulatory therapy.
This study has been recruiting since 05/2018.